Vensica Medical Raises $11M to Advance Needle-Free Overactive Bladder Treatment
Key Insights
Vensica Medical (search) secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (search) (OAB).
The funding round was led by Israel Biotech Fund (search) (IBF), with participation from Merz and Laborie (search), to advance a minimally invasive OAB treatment option.
Vensica's technology delivers Xeomin® directly to the bladder wall, potentially offering a more comfortable alternative to traditional injections for OAB patients.
Vensica Medical (search), a urology therapeutics company, has announced the closing of an $11 million funding round to support Phase 2 clinical trials of its needle-free treatment for overactive bladder (search) (OAB). The trials will take place across the United States and Europe.
The funding will support the development of Vensica's proprietary needle-free device that delivers botulinum toxin A (Xeomin®) directly to the bladder wall. This minimally invasive approach aims to provide a more comfortable and effective treatment option for patients suffering from OAB, a condition affecting millions worldwide.
The investment round was led by Israel Biotech Fund (search) (IBF), with strategic partners Merz, a neurotoxin company, and Laborie (search), a urology medical device company, also participating. This funding enables Vensica to further its mission of providing a simple and effective solution for individuals with OAB.
Needle-Free Delivery System
Vensica's technology uses a needle-free drug delivery system to administer Xeomin® directly to the bladder wall. This method is designed to be less invasive and more comfortable for patients compared to traditional injections, potentially transforming the standard of care for OAB. The company envisions its needle-free system as a platform for treating other bladder conditions.
Avner Geva, CEO of Vensica, stated, "We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder (search) treatment. This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it."
Strategic Partnership with Merz
As part of its partnership with Merz, Vensica has secured exclusive rights to use Xeomin® in needle-free therapeutic applications for various urologic indications. Vensica will also benefit from Merz's clinical development support. This collaboration marks a significant step in the company's goal of delivering next-generation urology treatments.
About Overactive Bladder
Overactive bladder (search) is a condition characterized by a frequent and urgent need to urinate, which can significantly impact a person's quality of life. Current treatments include medication, lifestyle changes, and, in some cases, injections of botulinum toxin A into the bladder muscle. Vensica's needle-free delivery system offers a potential alternative to these injections, aiming to reduce discomfort and improve patient compliance.